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IL-22 has multiple activities ranging from tissue repair to inflammation. To characterize 
the pathogenicity and plasticity of cells that produce IL-22, a novel reporter mouse 
strain was generated. Homeostatic IL-22 reporter expression was observed in intestinal 
lymphoid cells identified as CD4 T cells and ILC3 cells. In a model of inflammatory bowel 
disease, CD4 T cells strongly expressed the IL-22 reporter in mesenteric lymph node. 
To examine plasticity of IL-22+ T cells, they were purified after generation in  vitro or 
in vivo from inflamed colon, and then cultured under Th1, Th2, or Th17 conditions. In 
vitro-generated IL-22+ CD4 T cells showed relatively durable IL-22 expression under Th1 
or Th2 conditions, whereas in vivo-generated cells rapidly lost IL-22 expression under 
these conditions. In vitro-generated cells could not be diverted to express Th1 or Th2 
cytokines despite the expression of “master regulators.” In vivo-generated cells could 
be diverted, at very low frequency, to express Th1 or Th2 cytokines. Both in vitro- and 
in vivo-generated cells could be induced in vitro to express high levels of IL-17A and 
IL-17F, assigning them to a “Th17 biased” class. However, IL-27 potently downregulated 
IL-22 expression. To examine IL-22+ T cell pathogenicity, in vitro-generated cells were 
transferred into Rag1−/− mice, retaining the modest reporter expression and inducing 
moderate colitis. In contrast, IL-22 expressers from colitic mice, transferred into sec-
ondary hosts, lost reporter expression, acquired high T-bet and modest IFNγ and IL-17 
expression, and induced severe colitis. These findings are consistent with a model of 
strong polarization under optimal in vitro conditions, but a plastic state of T cells in vivo.
Keywords: il-22, Th17, Th22, T cell plasticity, il-27
inTrODUcTiOn
IL-22 was initially discovered as an IL-9- or activation-induced transcript in T cells (1). IL-22 per-
forms important roles in host defense through its action on epithelial cells eliciting innate immune 
reactions [reviewed in Ref. (2, 3)]. In contrast, roles of IL-22 in pathology of bowel (4, 5), liver (6), 
and skin (7) have also been reported.
A number of sources of IL-22 have been described. Among T cells [reviewed in Ref. (2)], 
a human subset designated “Th22” has been distinguished from Th17 cells and is a major IL-22 
producer (8, 9). This pattern in humans differs from the mouse, in which Th17 cells were reported to 
be major producers (7, 10). In man, Th1 cells were also shown to be capable of expressing IL-22 (11). 
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In the mouse, expression of IL-22 has also been reported inTh1 
cells (12), NKT cells (13, 14), and γδ T cells (15).
Several innate lymphocyte (ILC) subsets are reported to be 
IL-22 producers. These include NK cells in humans (16, 17) and 
mice (18, 19). Group 3 ILCs [reviewed in Ref. (20, 21)] consist 
of several subsets, most of them, including LTi cells (22, 23), are 
reported to be capable of producing IL-22. IL-22 production from 
other Group 3 ILC includes cells that express natural cytotoxicity 
receptors (NCR) (16, 18, 24–27) and NCR-negative ILCs (28, 29).
Transcription factors regulating murine IL-22 production 
include Stat3 that appears to be essential for expression in T 
cells (30, 31). Batf also appears to be required for expression 
and directly binds the IL-22 promoter (32). RORγt promotes 
expression, perhaps indirectly via upregulation of other recep-
tors [reviewed in Ref. (2)]. Stimulation of the aryl hydrocarbon 
receptor (AHR) also promotes expression, but does not appear to 
be essential [reviewed in Ref. (2)]. The Notch pathway promotes 
IL-22 expression through what is believed to be an indirect 
mechanism (33). Lastly, c-Maf is a transcriptional inhibitor of 
IL-22, acting downstream of TGFβ (34), and possibly mediates 
the IL-27 inhibitory effect (35).
IL-22 expression in murine T cells [reviewed in Ref. (2)] is 
induced by IL-23 or IL-6 and is inhibited by TGFβ (7). IL-22 can 
be strongly stimulated by the combination of IL-23, IL-6, and 
IL-1 (36) and by IL-21 (30). Expression is promoted by ligands 
of the AHR, such as 6-formylindolo(3,2-b)carbazole (FICZ) (37) 
combined with αIFNγ and αIL4 (38). Most of these studies have 
examined induction of IL-22 expression in vitro, whereas in vivo, 
it is less clear what factors positively and negatively regulate its 
expression, as well as the characteristics of the IL-22-expressing 
T cells. To examine IL-22 expression in vivo and to characterize 
IL-22-expressing T cells, an IL-22 reporter mouse would advance 
our understanding of these cells.
In the current study, we describe a novel IL-22 reporter 
mouse. This was developed to address several questions. 
What cells express IL-22 under homeostatic conditions 
and during immune and inflammatory responses? Do T 
cells expressing IL-22 represent a stable lineage pattern, 
or are they plastic and capable of responding to a different 
cytokine milieu? Because IL-22 has both protective and 
pathogenic properties, are IL-22-expressing T cells protec-
tive or pathogenic? Using the reporter, we conclude that the 
major IL-22 expressers in gut are ILC3s and CD4 T cells. 
CD4 T cells expressing IL-22 showed greater stability of IL-22 
expression when optimally polarized in vitro compared to those 
from an inflammatory site in  vivo. However, even optimally 
polarized T cells from in vitro cultures demonstrated consider-
able plasticity after transfer in vivo. Finally, IL-22-expressing T 
cells, transferred in vivo, demonstrated marked pathogenicity 
in gut tissue, accompanied by loss of IL-22 expression and gain 
of expression of other cytokines, such as IFNγ and IL-17A.
MaTerials anD MeThODs
Mice
C57BL/6 mice were purchased from the Animal Production 
Area, National Cancer Institute-FCRDC (Frederick, MD, USA). 
Rag1−/− were originally purchased from The Jackson Laboratory 
(Bar Harbor, MN, USA) and maintained by homozygous breed-
ing at NCI-Frederick. Three strains of IL-22-tdTomato mice have 
been produced at NCI, Frederick, MD, USA, and homozygous 
strains have been selected and maintained at the same animal 
facility. All mice used were 8–12  weeks old. NCI-Frederick is 
accredited by AAALAC International and follows the Public 
Health Service Policy for the Care and Use of Laboratory Animals. 
Animal care was provided in accordance with the procedures 
outlined in the Guide for Care and Use of Laboratory Animals 
(National Research Council; 1996; National Academy Press; 
Washington, DC, USA).
Flow cytometry and antibodies
To perform surface staining, 1 × 106 cells were placed in individual 
wells of a 96-well round bottom plate and incubated with the 
appropriate antibody cocktails for 15 min at 4°C on a slow rocker. 
After the staining, cells were fixed in a solution of 2% ultrapure 
formaldehyde (Polysciences, Inc., Warrington, PA, USA) in 
FACS buffer for 20 min on ice, washed twice, and analyzed the 
following day on the Canto II (BD Biosciences) or FACSCalibur 
(BD Biosciences). Intracellular staining was performed using 
Cytofix/Cytoperm Fixation/Permeabilization Solution Kit with 
BD GolgiStop (BD biosciences) according to the manufacturer’s 
instruction. Flow cytometry acquisition was performed on an 
LSRIISorp. Data were analyzed using FACS Express or FlowJo 
software (Tree Star, Inc., Ashland, OR, USA). Antibodies against 
CD45 (clone 30-F11, BD Pharmingen), CD3 (clone 145-2C11, 
BD Pharmingen), CD4 (clone GK1.5, BD Pharmingen), CD8 
(clone 5H10, Biolegend), T-bet (clone eBio4B10, eBioscience), 
IL-17A (clone ebio17B7, eBioscience), IL-4 (clone B11B, 
Biolegend), IFNγ (clone XMG 1.2, eBioscience), IL-22 (clone 
A3.6M, eBioscience and clone poly5164, Biolegend), TGF-β 
(clone 11A5, Biolegend), IL-17F (clone ebio18F10, eBioscience), 
NKP46 (clone 29A 1.4, Biolegend), c-Kit (clone 2B8, Biolegend), 
Sca-1 (clone D7, BD Pharmingen), and CD127 (clone A7R34, 
eBioscience) were used.
In Vitro T cell Differentiation
Purified CD4 T cells from mouse spleen cells were performed by 
Dynal® Mouse CD4 Cell Negative Isolation Kit (Life Technology) 
and cultured under Th22 conditions, including 1 μg/ml plate bound 
anti-CD3 (eBioscience), 0.5  μg/ml anti-CD28 (eBioscience), 
10 μg/ml anti-IL4 (Biolegend), 10 μg/ml anti-IFNγ (Biolegend), 
10  ng/ml IL-6 (Peprotech), 1  ng/ml TGF-β (Peprotech), and 
200 nM 6-formylindolo(3,2-b)carbazole (FICZ, Sigma-Aldrich) 
for 4 days. Cells were harvested and sorted for tdTomato signal 
by flow cytometry using a FACSAria and cultured under different 
Th1, Th2, Th17, and Th22 conditions. For Th1 and Th2 condition, 
cells were stimulated with 1 μg/ml plate bound anti-CD3, 0.5 μg/
ml anti-CD28 in the presence of 10 μg/ml anti-IL4 (Th1), 10 ng/
ml IL-12 (Peprotech, Th1), 10  μg/ml anti-IFNγ (Th2), 10  μg/
ml anti-IL12 (Biolegend, Th2), and 30  ng/ml IL-4 (Peprotech, 
Th2). For Th17 cell differentiation, cells were cultured with 1 μg/
ml anti-CD3, 0.5 μg/ml anti-CD28, 10 μg/ml anti-IL4, 10 μg/
ml anti-IFNγ, 10 ng/ml IL-6, 50 ng/ml IL-23 (R&D Biosystem), 
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and 1  ng/ml TGF-β (Peprotech). Three days after activation, 
cells were restimulated with 500  ng/ml ionomycin and 50  ng/
ml phorbol 12-myristate 13-acetate (Sigma-Aldrich) in the 
presence of GolgiStop for 5 h, after which IFNγ, IL-4, IL-17A, 
and IL-17F-producing cells were analyzed using a BDCytoFix/
CytoPerm intracellular staining kit (BD Biosciences) following 
the manufacturer’s instructions.
In Vitro-generated Th22 cell Transfer
Purified CD4 T cells cultured under Th22 polarization condition 
for 4 days, followed by sorting of tdTomato positive and tdTomato 
negative cells using a FACSAria (BD Biosciences). Sorted cells 
and CD4 T cells (cultured under neutralized condition for 4 days) 
were injected into the recipient mice (0.5 × 106 cells/mouse). Mice 
were monitored twice a week with body weight, stool consistency, 
and occult/gross blood in stool using Hemoccult Slides (Beckman 
Coulter, Fullerton, CA, USA). Tissues were harvested 1 month 
following cell transfer.
In Vivo-generated Th22 cell Transfer
Mesenteric lymph nodes were harvested from pre-colitis mice 
(4  weeks after CD4+CD45RBhigh cells were transferred into 
Rag1−/− mice, see Supplementary Material). IL-22 producing 
cells or non-producing cells were sorted of tdTomato fluorescent 
protein using FACSAria, followed by injection into second hosts 
(Rag1−/− recipients, 0.5 × 106 cells/mouse). Mice were monitored 
twice a week as described above, and tissues were harvested 
1 month following cell transfer.
rna extraction from Th22 cells and  
rT-Pcr
CD4 T cells were cultured under neutral (anti-CD3, anti-CD28) 
condition or Th22 conditions (anti-CD3, anti-CD28, anti-IL4, 
anti-IFNγ, 10 ng/ml IL-6, 1 ng/ml TGF-β, and FICZ) for 4 days, 
and sorted Th22 cells as described above were placed under Th1, 
Th2, Th17, and Th22 conditions for 3 days, followed by isolation 
of DNA-free total RNA using RNA II kit (MN) according to 
the provided protocol. Concentration and purity of RNA yield 
were established by spectrophotometry (Nanodrop, NanoDrop 
Technologies, Wilmington, DE, USA) and quality confirmed by 
electrophoresis. One microgram aliquots of each total RNA stock 
were converted into cDNA via hex primed reverse transcrip-
tion (Thermoscript RT kit, Invitrogen). Th22 transcripts were 
then analyzed for relative amounts of Il22, tdTomato, and 18s 
ribosomal RNA via Taqman Gene expression analyses (Applied 
Biosystems) using an ABI7300 thermocycler. Ct values generated 
from each sample with the 18s-specific probe set were used to 
normalize expression of the two target genes (Il22 and tdTomato) 
using a ΔCt method with correction for variation in amplifica-
tion efficiency. Inflammatory cytokines and transcription factors 
were analyzed by semiquantitative RT-PCR using oligonucleotide 
primers (Integrated DNA Technologies; Coralville, IA, USA), as 
described previously (39). Briefly, the amplified PCR fragments 
were separated by electrophoresis on 1.2% agarose gel and visu-
alized using SYBR Safe DNA gel stain (Invitrogen). To quantify 
the transcription levels, the amount of mRNA expression were 
normalized relative to the expression of HPRT mRNA using 
densitometric analysis by ImageJ 1.41 software.
gene Profile analysis of Th22 cells 
Treated with il-27
In vitro-generated Th22-tdTomato cells were cultured with or 
without mIL-27 (20 ng/ml, Cytokine) for 4 days. Following the 
ionomycin and PMA stimulation with the GolgiStop for 5 h, cells 
were harvested and proceeded with total RNA preparation. RNA 
was then transcribed (Reverse Transcription kit, Qiagen) and 
analyzed by either RT-PCR or micro array method using RT2 
Profiler PCR array  –  Th17 response array (PAMM-073Z plate, 
Qiagen) according to manufactures’ protocol.
histological analysis and scoring
Tissues (mesenteric lymph nodes, small and large intestine) from 
mice were fixed in 4% PFA overnight, replaced with 18% sucrose 
for 16–24 h, and then frozen for sectioned, and stained with either 
anti-RFP (abCam) or hematoxylin and eosin. H&E tissue sec-
tions were evaluated and graded in coded fashion by a veterinary 
pathologist (Miriam Anver). Semi-quantitative scale from 0 to 
4 was used where histopathological changes were identified as 
minimal = 1, mild = 2, moderate = 3, and severe = 4. For the 
colon, cumulative histopathology scores were calculated based on 
the sum of individual changes of parameters (crypt hyperplasia, 
goblet cell depletion, lymphocytic infiltrates, eosinophils, neu-
trophils, gut intraepithelial neoplasm, crypt abscess, and chronic 
active inflammation). For the small intestine, cumulative histo-
pathology scores were calculated based on the sum of individual 
changes of parameters (crypt hyperplasia, crypt loss, lymphocytic 
infiltrates, and chronic active inflammation).
statistics
Statistical analysis was performed using the GraphPad Prism 
6.0 software. Data are expressed as mean ±  SEM. The Student 
two-tailed unpaired, parametric t test was used to assess statisti-
cal differences between two groups. Asterisks indicate statistical 
differences, *p < 0.05, **p < 0.01, and ***p < 0.001.
resUlTs
il-22 reporter construction and 
Transgene expression
A murine IL-22 reporter transgene was created using recom-
bineering to modify a bacterial artificial chromosome, as previ-
ously described (40), introducing tdTomato into exon 1 (Figure 
S1 in Supplementary Material). Because the signal sequence was 
disrupted by design, this results in accumulation of the reporter 
in expressing cells, enabling their detection and isolation by flow 
cytometry. The transgene was introduced into C57Bl/6 mice by 
standard methods, and several founder lines were bred to homozy-
gosity. The selected founder line showed fidelity of expression to 
the endogenous IL-22 gene by several criteria as follows. In vitro, 
reporter expression was induced in CD4 T cells by the same com-
bination of stimuli as the IL-22 gene (Figure 1A), and there was a 
similar quantitative expression of reporter transcripts compared 
FigUre 1 | correspondence of il-22 reporter expression to endogenous il-22. (a) Spleen CD4+ T cells from reporter mice were cultured 4 days in the 
presence of IL-22-inducing conditions (FICZ + IL-6 + anti-IL-4 + anti-IFNγ + IL-23). Cells were treated with GolgiStop for 5 h and stained for intracellular IL-22 or 
analyzed for the tdTomato reporter by real-time RT-PCR (data are expressed as mean ± SEM). Numbers in quadrants indicate percent of CD3+ cells. Data indicate 
three independent experiments. (B) In vivo expression of IL-22 or reporter in different tissues. Cells were examined for the tdTomato reporter or stained with 
anti-IL-22. MLN, mesenteric lymph node; ALN, axillary lymph node; PP, Peyers patch; IEL, intraepithelial cells isolated from small intestine; LP, lamina propria cells 
purified from small intestine. Numbers in quadrants indicate percent of lymphocyte cells. Data are representative of two or more experiments.
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to the endogenous IL-22 gene measured by quantitative RT-PCR. 
In vivo, the same lymphoid subsets expressed the reporter and 
IL-22 (Figure 1B) mostly in lamina propria (LP) cells from gut, 
but not other gut-associated lymphoid tissue (GALT), axillary 
lymph node (ALN), spleen, or thymus.
Phenotype of lymphoid cells expressing 
the il-22 reporter
Lymphoid cells from LP were analyzed for markers on cells 
expressing the IL-22 reporter under homeostatic conditions. The 
more frequent population was ILC3, identified by the criteria 
that they expressed IL-7R and lacked CD3 (Figure  2A). The 
less frequent population was CD4 T cells (Figure 2A; Figure S2 
in Supplementary Material). Both populations expressed Sca1, 
neither expressed cKit, NKp46, or CD8. To examine inflamed 
tissue, colitis was induced by transfer of reporter CD4+CD45Rbhi 
T cells into Rag1−/− mice. The initially transferred T cell popula-
tion from spleen contained very few reporter-positive cells 
(Figure 2B). Four weeks after transfer, mice were precolitic and 
showed an expansion of IL-22 reporter T cells in MLN, LP, IEL, 
and spleen (Figure  2B). At the onset of colitis, 8  weeks after 
T cell transfer, the tdTomato signal diminished in mesenteric 
lymph nodes (declining by 6 weeks as seen in Figures S3A,B in 
Supplementary Material), indicating that IL-22 itself was not 
directly associated with gut pathology, as will be discussed in a 
later section.
il-22-expressing T cells: stronger 
Polarization In Vitro than In Vivo
To evaluate plasticity of the IL-22 lineage when generated 
in vitro, CD4 T cells were first cultured 4 days under IL-22 condi-
tions (αCD3 + αCD28 + FICZ + IL-6 + IL-23 + αIL-4 + αIFNγ). 
Expressing cells were then enriched by sorting and placed in  secondary 
cultures for 3  days under conditions favoring  differentiation into 
other CD4 subsets, such as Th1, Th2, or Th17. Three days of Th1 cul-
ture conditions neither extinguished IL-22 reporter  expression nor 
induced expression of the Th1 signature cytokine IFNγ (Figure 3A) 
compared to positive controls (Figure 3A; Figure S4 in Supplementary 
FigUre 2 | identification of il-22-producing T cells and innate lymphoid cells in normal lP and inflamed galT. (a) Lymphoid cells from LP of 
unmanipulated IL-22 reporter mice were stained for different markers of innate lymphocytes and T cells. (B) CD4+CD45Rbhi T cells of reporter mice were transferred 
into Rag1−/− mice and lymphoid cells from gut-associated lymphoid tissue were examined 4 weeks later (n = 4, data representative of three independent 
experiments). Numbers in quadrants indicate percent of CD45+ cells.
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Material). Th2 culture conditions similarly failed to extinguish 
IL-22 reporter expression or induce expression of the Th2 signature 
cytokine IL-4. On the other hand, IL-17 was coexpressed in about 
15% of cells following the initial “IL-22” culture and increased under 
subsequent Th17 culture conditions, although some IL-17 expressers 
extinguished IL-22 reporter expression. Other cytokines and recep-
tors were examined at the level of transcripts (Figure 3B), the only 
one showing major modulation was IL-10, which was upregulated 
under Th2 or Th17 conditions. These results indicate that T cells 
induced in vitro to express IL-22 were strongly polarized away from 
the Th1 or Th2 lineages. On the other hand, the  relationship with 
Th17 expression is consistent with a single lineage capable of both 
IL-22 and IL-17 expression depending on environmental signals. We 
will use the term “Th22” merely as a convenient term to describe T 
cells currently expressing the IL-22 reporter.
Having examined the plasticity of T cells expressing IL-22 
under different conditions, these cells were examined further 
for expression of, what had been termed “master regulators,” 
transcription factors known to control genes of the major subsets 
(Figure 3C; Figures S5 and S6 in Supplementary Material). The 
master regulators for Th1, Th2, Th17, and Tregs are T-bet, Gata3, 
RORγt, and FoxP3, respectively. RORγt, high under IL-22 condi-
tions, remained relatively stable under subsequent Th1, Th2, or 
Th17 conditions, perhaps contributing to the relative stability of 
IL-22 expression. We noted that RORγt was not uniquely high 
in Th22 cells but was also high in normal spleen or Th17 cells 
(Figure S6 in Supplementary Material). Gata3 expression was 
extremely low in IL-22-expressing T cells and not increased in 
subsequent Th2 conditions, accounting in part for the absence 
of IL-4 expression. On the other hand, T-bet was relatively well 
FigUre 3 | il-22-producing T cells generated in vitro: stability in 2° Th1, Th2, or Th17 culture.  
 
(Continued)
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expressed together with IL-22 in the first and subsequent cultures, 
but was not accompanied by IFNγ expression (Figures 3A,B), 
indicating it is insufficient as a “master regulator.” FoxP3, 
required for Tregs, was extremely low in Th22 cells. High TGFβ 
expression was observed under all conditions, including normal 
spleen (Figure S6 in Supplementary Material), and thus was not 
unique to Th22 cells. Comparison with conventional Th1, Th2, 
and Th17 cells (Figure 5A in Supplementary Material) shows 
that in cells from conventional Th1, Th2, and Th17 cultures, 
their signature cytokines, IFNγ, IL-4, and IL-17A/F, are higher 
than in cells derived from Th22 cultures recultured under the 
same conditions. Thus, the Th22 bias generated from optimal 
cultures was relatively stable in secondary cultures optimal for 
other subsets.
Several transcription factors that are thought to regulate 
IL-22 expression were evaluated for plasticity, including 
the positive regulator and AHR, and the negative regulator 
c-Maf (Figure 3C). AHR was strongly expressed in Th22 cells 
and somewhat suppressed under subsequent Th1 and Th17 
conditions, and yet, despite its usual positive association with 
IL-22, was not accompanied by downregulation of IL-22. 
c-Maf was expressed in Th22 cells and strongly increased by 
Th1 conditions, but despite its association with inhibiting 
IL-22 expression was not accompanied by downregulation of 
IL-22. Expression of the membrane protein ICOS, which has 
been associated with IL-22 expression, was strongly expressed 
in Th22 cells, but little affected by subsequent culture 
conditions. Comparing recultured Th22 cells to cells from 
primary cultures favoring Th1, Th2, or Th17 (Figure S5B in 
Supplementary Material) showed the latter transcribed much 
higher levels of signature regulators including T-bet, GATA3, 
RORγt, and FoxP3.
Having analyzed plasticity of IL-22 expressers generated 
in  vitro, we next examined IL-22 expressers generated in a 
pathological setting in vivo by colitis induction. CD4 T cells from 
reporter mice were injected into Rag1−/− hosts to induce colitis. 
Four weeks later, IL-22-reporter-expressing T cells were purified 
from MLN and placed into Th1, Th2, or Th17 culture conditions. 
Under Th1 or Th2 conditions, these cells showed considerably 
less stability of reporter expression (Figures 4B,C; Figure S8 in 
Supplementary Material) than did IL-22 expressers generated 
in vitro (Figure 4A) and acquired modest expression of Th1 or 
Th2 cytokines. This suggests that T cells, under physiological or 
pathological conditions, may retain much more plasticity than 
suggested by optimal priming in vitro.
Pathogenicity of Th22 cells
IL-22, under different conditions has been reported to promote 
epithelial repair, or on the other hand, to promote inflammation. 
To evaluate the pathogenicity of in vitro-generated Th22 cells, a 
colitis model was used.
In Vitro-Generated Th22
T cells were cultured under IL-22-promoting conditions, purified 
for IL-22 reporter expression, and transferred into Rag1−/− recipi-
ents to generate colitis. Four weeks later, analysis of GALT showed 
that a small fraction of transferred CD3+ cells had retained 
reporter expression (Figures 5A,B) or IL-22 transcripts (Figure 
S8 in Supplementary Material). A very small fraction expressed 
IL-17A, and none expressed IFNγ or IL-4. T cells derived from 
IL-22 expressers induced an inflammatory response in both 
small and large bowel, which was significantly stronger than 
that induced by IL-22 negative cells from the same culture, or 
CD4 T cells from “neutral cultures” (Figures 5C,D). By “neutral 
culture,” we refer to polyclonally stimulated T cells, but without 
other culture conditions favoring a particular subset. Thus, we 
blocked IFNγ and IL-4, and did not add cytokines favoring dif-
ferentiation into different subsets. This seemed like a reasonable 
control for Th22 culture conditions, and the transferred “neutral” 
cells showed less pathogenicity compared to sorted Th22 cells. 
Note that T-bet was not detected in the mice receiving Th22 
cells generated in vitro (Figure 5E); this may have relevance by 
comparison to in vivo-generated Th22 as will be shown.
In Vivo-Generated Th22
Since in vitro- and in vivo-generated Th22 cells differed in their 
plasticity, we compared their pathogenicity. Two successive 
T cell transfers (each of 4  weeks) were used to evaluate Th22 
cells. In the first transfer, T cells from IL-22 reporter mice were 
transferred into Rag1−/− mice to generate Th22 cells in vivo. Four 
weeks later at the precolitic stage, these in vivo-generated Th22 
cells were purified from mesenteric lymph node and transferred 
into secondary Rag1−/− recipients and analyzed 4  weeks later. 
Exceedingly, few of the transferred CD3+ cells retained reporter 
expression in GALT 4 weeks after secondary transfer (Figure 6A). 
Moreover, some of the transferred T cells had gained expression 
of IFNγ, IL-17A, and IL-17F, while losing IL-22 reporter expres-
sion (Figure 6B). This is consistent with preceding results show-
ing that IL-22 expressers that are optimally polarized in vitro do 
not reflect the greater plasticity of T cells under physiological or 
pathological conditions that occur in vivo. On the other hand, 
T cells from IL-22 reporter mice or non-reporter WT mice were generated in a 1° culture as shown in Figure 1A and sorted for reporter expression. Th1, Th2, or 
Th17 cells were generated in control 1° cultures. Sorted cells from 1° Th22 cultures (or control Th1, Th2, or Th17 cultures) were then placed in a 2° culture for 
3 days under Th1 (αCD3, αCD28, αIL-4, IL-12), Th2 (αCD3, αCD28, αIFNγ, IL-4), or Th17 (αCD3, αCD28, αIL-4, αIFNγ, IL-6, IL-23, TGF-β, and IL-1β) conditions.  
(a) Cells were treated with GolgiStop and stained for IFNγ, IL-4, or IL-17, and analyzed for IL-22 reporter expression. Numbers in quadrants indicate percent of 
CD45+ cells. (B) Cells were analyzed for expression of cytokines. Data represent mean ± SEM (n = 6 total samples cumulative from two separate experiments), 
*p < 0.05, **p < 0.01, and ***p ≤ 0.001; ns, not significant, determined by t-test. (c) Cells were analyzed for expression of what were formerly called “master 
regulators” T-bet, Gata3, RORγt, FoxP3, or the membrane protein ICOS or transcription factors AHR or cMaf, an inhibitor of IL-22 expression. Gene expression was 
normalized to Hprt levels. Data are expressed as mean ± SEM (n = 8 total samples cumulative from two separate experiments), *p < 0.05, **p < 0.01, and 
***p ≤ 0.001; ns, not significant, determined by t-test. Data represent two independent experiments.
FigUre 3 | continued
FigUre 4 | stability of il-22 production comparing T cells generated in vitro versus in vivo. T cells expressing the IL-22 reporter were generated (a) in vitro 
for 4 days under conditions as shown in Figure 1 or (B,c) in vivo in pre-colitic mice as shown in Figure 2, at 4 weeks. Cells were sorted for reporter expression, 
placed in Th1, Th2, or Th17 culture conditions (as shown in Figure 3) for various times then analyzed for reporter expression. Numbers in quadrants indicate 
percent of CD4+ cells (a,B), and lymphocyte cells (c). Bar graph represents percentage of CD4 T cells (n = 3), and plotted as mean ± SEM. *p < 0.05 and 
***p ≤ 0.001; ns, not significant, determined by t-test. Data are indicative of three independent experiments.
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colitis was much more strongly induced by in vivo than in vitro 
Th22 (Figures  6C,D; Figure S7 in Supplementary Material). 
Pathogenicity may reflect the modest switch to expression of 
the pathogenic cytokines IFNγ, IL-17A, and F (Figure  6B), 
although in other models of inflammatory bowel disease (IBD), 
the percentage of IFNγ producers can be much higher (41). 
FigUre 5 | stability of il-22 production and pathogenicity by in vitro-generated Th22 cells transferred in vivo.  
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T cells expressing the IL-22 reporter were generated in vitro for 4 days. Cells were sorted for reporter expression and mice received cells from a “neutral culture” 
(αIFNγ + αIL-4 + αCD3 + αCD28) versus sorted IL-22 (+) or (−) cells from a Th22 culture as shown in Figure 1. Four weeks after receiving reporter-positive cells 
and inducing colitis (a), T cells from GALT were analyzed for reporter expression. Numbers in quadrants indicate percent of CD45+ cells. Data are representative of 
two experiments. (B) Different cytokines were determined in LP cells by intracellular staining and flow cytometry. Numbers in quadrants indicate percent of CD45+ 
cells. Note: comparing (a,B), tdTomato fluorescence was somewhat reduced by fixation and permeabilization in (B). Data are representative of two experiments.  
(c) Intestinal tissues were evaluated histologically for ileitis and colitis. Histopathological scores were determined for the distal colon and distal small intestine (n = 8 
total mice per group cumulative from two separate experiments). (D) H&E staining for representative sections in which “Rag1−/−” shows control sections from mice 
that received no T cells. (e) Flow cytometry analysis of T-bet in lamina propria cells from Rag1−/− mice receiving Th22 or non-Th22 cells. Numbers in quadrants 
indicate percentage of CD45+ cells. Data are representative of two experiments.
FigUre 5 | continued
The decrease in IL-22 reporter expression could also account 
for increased pathogenicity (compare Figures  6B and 5B) if 
IL-22 had a protective effect. The striking upregulation of T-bet 
(Figure 6E) may account for increased IFNγ or other pathogenic 
features.
effect of il-27 on Th22 cells
IL-22 expression by human T cells was recently reported to 
be suppressed by IL-27 (42). In the mouse, it has been shown 
that IL-27 can inhibit Th17 development (43, 44). IL-27 recep-
tor transcripts were detected (Figure  3B), so we evaluated the 
effect of IL-27 on Th22 first generated in  vitro. IL-27 strongly 
inhibited IL-22 expression (Figure 7A). This is consistent with 
observed reductions in RORγt and AHR and upregulation of 
TGFβ (Figure 7B). The cytokine profile shifted to a generally less 
inflammatory pattern showing reductions in IL-17s, Ccl2, Ccl5, 
and IL-9, and increased IL-10 and IL-27 itself (Figure 7C).
DiscUssiOn
A novel IL-22 reporter mouse was developed, enabling us to 
purify expressing cells and examine their properties, including 
plasticity, lifespan, and pathogenicity. Under homeostatic condi-
tions, IL-22 reporter expression was prominent in the GALTs 
in ILCs and CD4T cells. T cell expression was relatively stable 
if IL-22 expression was induced in vitro, but not in vivo. There 
was strong association with the capacity to express IL-17 and 
no coexpression with IFNγ or IL-4 during in vitro cultures that 
can promote expression of the latter. These findings are consist-
ent with a single T cell lineage having the capacity to express 
either or both IL-22 and IL-17, which is distinct from Th1 and 
2 lineages. IL-22-expressing T cells, generated in vivo or in vitro, 
induced IBD following transfer in vivo. Transferred T cells were 
shown to persist in  vivo for at least 2  months, although losing 
IL-22 expression. Although loss of IL-22 expression could be 
explained by expansion of contaminating IL-22-reporter negative 
cells, cytokines are not constitutively expressed by T cells, so it 
is reasonable to interpret this as loss of IL-22 expression from a 
lineage previously expressing it.
The complex regulation of IL-22 expression in T cells has been 
the subject a very thorough review (2). There are many dem-
onstrated regulators of IL-22 expression in these cells. Positive 
extracellular stimuli include IL-6, IL-23, IL-21, IL-1β, IL-18, and 
Notch ligands. TGFβ and the ICOS pathway are negative stimuli. 
Transcription factors include STAT3 and Batf, which are essen-
tial, AHR and RORγt, which augment expression, and c-Maf 
and IRF4, which inhibit. The relative stability of the mouse Th22 
phenotype that was generated in vitro could relate to persistence 
of receptors or transcription factors. Phenotypic stability could 
also relate to epigenetic modifications of the IL-22 gene itself as 
has been discussed in the context of other cytokine genes in T cell 
subsets (45), and it will be interesting to analyze the IL-22 gene 
for such modifications.
A recent study employed a fate reporter for IL-22 (46), in 
which cells were permanently marked after activating the IL-22 
locus. As in our study, gut ILC3s were marked under homeostatic 
conditions. In the T cell lineage, perhaps because that reporter 
was slow to react, there was little homeostatic expression or 
in  vitro induction. However, under inflammatory conditions, 
marked CD4 cells, as in our study, could express IFNγ, consistent 
with plasticity, rather than fidelity to a stable Th22 lineage.
Our findings contrast with some others regarding the expres-
sion of NKp46 on ILCs expressing IL-22. We observed background 
staining for NKp46 (Figure 2) (using two different antibodies), 
similar to that of Sonnenberg et  al. (3, 29) p. 202. However, 
other studies have observed IL-22 expression from NKp46+ ILCs 
[reviewed in Ref. (25) p. 203]. These discrepancies may partly 
arise not only from the differences in animal colonies or isolation 
procedures but also from the frequent use of stimulants ex vivo 
(such as IL-23), whereas our observations are on cells directly 
isolated from mucosa.
Although early studies had concluded that in vitro-generated 
Th1 and Th2 cell types were not interconvertible (47, 48), more 
recent studies in vivo reveal, for example, Th2 reprograming to 
express Th1 features (49). Th17 cells were reported to be non-
plastic in one study in vivo (50), whereas a number of studies 
in vivo reported plasticity (51–53). In our study of CD4 IL-22 
expressers, reprograming appeared to be inversely correlated 
with intensity of polarization. “Strong” in  vitro polarization 
yielded cells with relatively durable IL-22 expression under 
Th1 or 2 culture conditions. “Weaker” in vivo polarization in 
inflamed tissue yielded IL-22 expressers that lost expression 
under Th1 or 2 culture conditions. This variable range of polari-
zation is reminiscent of Th1, Th2, and Th17 phenotypes which 
also become strongly polarized with optimal stimuli in  vitro 
and were once thought to be stable lineages [reviewed in Ref. 
(45)]. However, T  cells in an in  vivo milieu, as in our study, 
appear less differentiated and have more stem-like properties 
(54), with the potential for a broad repertoire of responses 
regulated by the cytokine milieu at the moment. Even more 
strongly polarized IL-22 expressers generated in  vitro lost 
expression when transferred into an inflammatory milieu 
FigUre 6 | instability of il-22 production and high pathogenicity of in vivo-generated Th22 cells transferred into secondary hosts.  
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FigUre 7 | il-27 effects on products of il-22 expressers. T cells 
expressing the IL-22 reporter were generated in vitro as shown in Figure 1. 
Cells were sorted for reporter expression and treated with IL-27 under 
conditions favoring IL-22 expression or other Th differentiation conditions for 
4 days and evaluated for transcripts by PCR. (a) IL-22 expression. Data are 
analyzed by regular PCR (left panel) or real-time PCR (right panel, mean ± SEM, 
n = 3). (B) Regulators and transcription factors were examined by qPCR. 
Gene expression was normalized to Hprt levels. Data are expressed as 
mean ± SEM (n = 3) *p < 0.05, **p < 0.01, and ***p ≤ 0.001; ns, not significant, 
determined by t-test. Data are representative of two independent experiments. 
(c) Cytokines from IL-27-treated Th22 cells were evaluated by microarray 
using Th17 response PCR array. Data represent the fold changes compared 
to non-treated cells. Data are representative of two independent experiments.
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in vivo. The loss of IL-22 expression that we observed in vivo 
could be due to several possible mechanisms. Loss of expres-
sion could be due to cytokines that suppress, such as TGFβ or 
IL-27 as shown here. Loss of expression could also be due to 
insufficient levels of inducing cytokines, such as IL-23 or IL-6, 
or to other unknown mechanisms.
Human Th22 cells exhibit less plasticity than mouse T cells 
expressing IL-22 and were reported to maintain IL-22 expression 
under Th1 or 2 culture conditions (55). Also, in contrast to IL-17 
induction that was readily induced in mouse IL-22 expressers in 
our experiments, human Th22 cells were not amenable to IL-17 
induction (55) (although some human Th17 coexpress IL-22). 
Thus, human “Th22” cells appear to constitute a subset distinct 
from Th17 cells (9), whereas mouse cells, from our data are “Th17 
biased” (Figures 3A,B).
Although IL-22 expression could be extinguished under 
Th1 or Th2 culture conditions, we did not observe induction 
of Th1 or Th2 signature cytokines, IFNγ or IL-4, respec-
tively, under in  vitro conditions (Figures  3A,B). However, 
under inflammatory conditions, in vivo, IFNγ and IL-4 were 
induced from these cells (Figure 6), perhaps contributing to 
the pathogenicity of the transferred cells (Figure  6). In the 
mouse, primary T cells had been reported to express IL-22 
transcripts after culture under Th1 (but not Th2) conditions 
(11); however, IL-22 protein was detected only under Th17, but 
not Th1 or 2 conditions (10). Human T cells have been reported 
to coexpress IFNγ (but not IL-4) with IL-22 (8, 9). Perhaps sur-
prisingly, T-bet, the “master regulator” of IFNγ, was relatively 
well expressed together with IL-22 in the first and subsequent 
cultures, but was not associated with IFNγ expression, in 
contrast to other conditions reporting coexpression (36). This 
could be explained by a lack of accessibility of the IFNγ gene 
due to a failure of pioneer nuclear factors to render its opening 
(45). This illustrates the point that the term “master regulator” 
is overly simplistic as has been shown experimentally in several 
lineages (56, 57).
Pathogenicity of Th22 cells was manifested as severe IBD 
following transfer into Rag1−/− mice. This pathogenicity was 
considerably greater if the Th22 cells derived from precolitic 
mice (Figure 6) than from Th22 cultures (Figure 5); however, the 
former would have TCR specificities for gut microbiota, whereas 
the latter would have random TCR specificities. Although IL-22 
has been shown to contribute to pathogenicity in some models 
(6, 7, 28), pathogenicity of Th22 cells in our experiments seems 
unlikely to be due to IL-22 itself. Although our experiments do 
not directly address whether IL-22 itself is pathogenic, we suggest 
that it is not pathogenic because its expression does not correlate 
with disease by several criteria. First, the peak of IL-22 expression 
in colon and ileum (Figure S3A in Supplementary Material) at 
4 weeks after transfer precedes the peak of pathology at 8 weeks. 
(a) T cells from IL-22 reporter mice were first transferred into Rag1−/− mice to induce colitis. Four weeks later, MLN T cells expressing the IL-22 reporter were 
transferred to secondary hosts. After 4 weeks in mice receiving IL-22 reporter-positive cells (a), T cells from gut-associated lymphoid tissues were analyzed for 
reporter expression. Numbers in quadrants indicate percentage of CD45+ cells. Data are representative of two experiments. (B) Intracellular cytokines were 
examined in lamina propria cells by flow cytometry. Numbers in quadrants indicate percent of CD45+ cells. Data are representative of two experiments. (c) Intestinal 
tissues were evaluated histologically for inflammatory bowel disease. Histopathological scores were determined for the distal colon and distal small intestine (n = 8 
total mice per group cumulative from two separate experiments). (D) H&E staining for representative sections. (e) Flow cytometry analysis of T-bet in lamina propria 
cells from in vivo transfer of T cells expressing or not expressing the IL-22 reporter. Numbers in quadrants indicate percentage of CD45+ cells. Data are 
representative of two experiments.
FigUre 6 | continued
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